首页|Second Xiangya Hospital of Central South University Reports Findings in Bladder Cancer (Establish TIIC signature score based the machine learning fusion in blad der cancer)
Second Xiangya Hospital of Central South University Reports Findings in Bladder Cancer (Establish TIIC signature score based the machine learning fusion in blad der cancer)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Oncology - Bladder Can cer is the subject of a report. According to news originating from Hunan, People ’s Republic of China, by NewsRx correspondents, research stated, “Bladder cancer is a prevalent malignant tumor with high heterogeneity. Current treatments, suc h as transurethral resection of bladder tumor (TURBT) and intravesical Bacillus Calmette-Guerin (BCG) therapy, still have limitations, with approximately 30% of non-muscle-invasive bladder cancer (NMIBC) progressing to muscle-invasive bla dder cancer (MIBC), and a substantial number of MIBC patients experiencing recur rence after surgery.”
HunanPeople’s Republic of ChinaAsiaBladder CancerCancerCyborgsDrugs and TherapiesEmerging TechnologiesGe neticsHealth and MedicineImmunotherapyMachine LearningOncology
NETL
NSTL
